Omnicell (OMCL) Lowered to “Hold” at Craig Hallum

Craig Hallum lowered shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a research report released on Friday, February 2nd.

Several other research firms also recently commented on OMCL. Cantor Fitzgerald raised their price target on shares of Omnicell to $58.00 and gave the stock an overweight rating in a research note on Friday, October 27th. Oppenheimer reaffirmed a buy rating and issued a $55.00 price objective on shares of Omnicell in a research report on Thursday, October 19th. BidaskClub downgraded shares of Omnicell from a sell rating to a strong sell rating in a research report on Friday, January 19th. Finally, Zacks Investment Research cut shares of Omnicell from a hold rating to a strong sell rating in a research note on Wednesday, November 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $56.14.

Omnicell (OMCL) opened at $44.05 on Friday. Omnicell has a 12-month low of $36.65 and a 12-month high of $55.40. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.28 and a current ratio of 1.73. The firm has a market cap of $1,670.00, a price-to-earnings ratio of 86.37, a P/E/G ratio of 3.63 and a beta of 0.65.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.54 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.02. The business had revenue of $198.26 million during the quarter, compared to analyst estimates of $205.50 million. Omnicell had a net margin of 2.88% and a return on equity of 1.54%. Omnicell’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.37 earnings per share. analysts expect that Omnicell will post 0.77 EPS for the current year.

In related news, CFO Peter J. Kuipers sold 1,926 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $51.69, for a total value of $99,554.94. Following the completion of the sale, the chief financial officer now owns 40,544 shares of the company’s stock, valued at approximately $2,095,719.36. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.77% of the stock is currently owned by insiders.

Several hedge funds have recently made changes to their positions in OMCL. Carillon Tower Advisers Inc. acquired a new position in shares of Omnicell during the 4th quarter valued at about $38,612,000. Janus Henderson Group PLC boosted its position in shares of Omnicell by 129.6% during the 2nd quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock valued at $53,096,000 after acquiring an additional 695,334 shares during the last quarter. Eagle Asset Management Inc. lifted its position in Omnicell by 36.8% in the fourth quarter. Eagle Asset Management Inc. now owns 1,365,794 shares of the company’s stock valued at $66,047,000 after buying an additional 367,687 shares during the last quarter. Kennedy Capital Management Inc. lifted its position in Omnicell by 199.2% in the fourth quarter. Kennedy Capital Management Inc. now owns 465,483 shares of the company’s stock valued at $22,576,000 after buying an additional 309,913 shares during the last quarter. Finally, Braun Stacey Associates Inc. acquired a new position in Omnicell in the fourth quarter valued at about $9,391,000.

WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/20/omnicell-omcl-cut-to-hold-at-craig-hallum.html.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply